SCHEMBL16709803

SCHEMBL16709803

Cn1nc(C(=O)O)c2c1-c1cc(F)cc(F)c1OC2

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 7/20 0.40
▸ PIK3CD O00329 2/20 0.38
▸ PIK3R2 O00459 2/20 0.38
▸ PIK3CA P42336 2/20 0.38
▸ PIK3CB P42338 2/20 0.38
▸ PIK3CG P48736 2/20 0.38
▸ PIK3R5 Q8WYR1 2/20 0.38
▸ PIK3R3 Q92569 2/20 0.38
▸ MAPT P10636 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ NOTUM Q6P988 3/20 0.36
▸ PGR P06401 2/20 0.35
▸ AR P10275 2/20 0.35
▸ NR3C1 P04150 1/20 0.35
▸ CCNA2 P20248 1/20 0.34
▸ CDK2 P24941 1/20 0.34
▸ CCNA1 P78396 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16709807 0.89 NOTUM (0.47) NR1H4PIK3CDPIK3R2PIK3CAPIK3CB
SCHEMBL2173369 0.81 NR1H4 (0.53) NR1H4PIK3CDPIK3R2PIK3CAPIK3CB
SCHEMBL16709827 0.80 NR1H4 (0.45) NR1H4PIK3CDPIK3R2PIK3CAPIK3CB
SCHEMBL2171176 0.78 MAPT (0.46) NR1H4PIK3CDPIK3R2PIK3CAPIK3CB
SCHEMBL16709805 0.77 NR1H4 (0.45) NR1H4MAPTPOLBNOTUMPGR
SCHEMBL16709826 0.74 POLB (0.44) NR1H4PIK3CDPIK3R2PIK3CAPIK3CB
SCHEMBL2174453 0.72 MAPT (0.64) NR1H4MAPTPOLBTP53
SCHEMBL16709822 0.72 NR1H4 (0.51) NR1H4MAPTPOLBTP53THRB
SCHEMBL16709823 0.71 NR1H4 (0.55) NR1H4MAPTPOLBNOTUMTP53
SCHEMBL21165153 0.71 NR1H4 (0.58) NR1H4MAPTPOLBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210253534-A1 COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) 2021-08-19 — — US disclosed
US-11021446-B2 Compositions and methods for modulating farnesoid X receptors NOVARTIS AG (CH) 2021-06-01 — — US disclosed
US-20200247757-A1 COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. 2020-08-06 — — US disclosed
US-10683271-B2 Compositions and methods for modulating farnesoid X receptors NOVARTIS AG (CH) 2020-06-16 — — US disclosed
EP-3065738-B1 COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS NOVARTIS AG (CH) 2018-02-28 — — EP disclosed
US-20170275256-A1 COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2017-09-28 — — US disclosed
US-20170275256-A1 COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2017-09-28 — — US disclosed
US-9682939-B2 Compositions and methods for modulating farnesoid X receptors NOVARTIS AG (CH) 2017-06-20 — — US disclosed
US-9682939-B2 Compositions and methods for modulating farnesoid X receptors NOVARTIS AG (CH) 2017-06-20 — — US disclosed
US-20160340317-A1 COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS NOVARTIS AG (CH) 2016-11-24 — — US disclosed
US-20160340317-A1 COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS NOVARTIS AG (CH) 2016-11-24 — — US disclosed
WO-2015069666-A1 COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS IRM LLC (BM) 2015-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11021446-B2 Compositions and methods for modulating farnesoid X receptors NR1H4, GPBAR1, SLC10A1 NR1H4 1/4885PIK3CD 1374/4885PIK3R2 1199/4885
US-20210253534-A1 COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS NR1H4, GPBAR1, SLC10A1 NR1H4 1/4885PIK3CD 1374/4885PIK3R2 1199/4885
US-20200247757-A1 COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS NR1H4, GPBAR1, SLC10A1 NR1H4 1/4885PIK3CD 1374/4885PIK3R2 1199/4885
US-20160340317-A1 COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS NR1H4, GPBAR1, SLC10A1 NR1H4 1/4885PIK3CD 1374/4885PIK3R2 1199/4885
US-20170275256-A1 COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS NR1H4, GPBAR1, SLC10A1 NR1H4 1/4885PIK3CD 1374/4885PIK3R2 1199/4885
US-10683271-B2 Compositions and methods for modulating farnesoid X receptors NR1H4, GPBAR1, SLC10A1 NR1H4 1/4885PIK3CD 1374/4885PIK3R2 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback